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Bipolar disorders represent an illness not easily treated by
monotherapy. Approximately 2/3 of patients are not ade-
quately responsive to lithium monotherapy and the great
majority of patients require (and get) additional medica-
tion: additional mood stabilizers [1], antipsychotics [2],
antidepressants, antimanic and/or hypnotic substances
[3,4]. These traditional additional drugs are associated
with potential problems. Antidepressants may precipitate
mixed states or mania and/or cause cycle acceleration and
rapid cycling. Conventional neuroleptics are associated
with switching into depression, and clearly increase the
individual risk of extrapyramidal symptoms, such as tar-
dive dyskinesia. Polypharmacy is associated with the risk
of unwanted pharmacological interactions: specific risks
in antibipolar treatment are discussed.
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